.@michael_lidsky of @DukeSurgOnc and @DukeCancer is leading EA2222/PUMP, a randomized phase 3 study for patients with #Colorectal liver metastases. Learn more: https://bit.ly/ea2222-pump cc: @CCAlliance, @FightCRC, @NCCRTnews
EA8231 is a phase 3 study comparing pembrolizumab & sacituzumab govitecan vs. standard chemotherapy in patients with advanced #UrothelialCancer. The trial aims to improve treatment options & guide further research. ➡️ https://bit.ly/ea8231-study cc: @BladderCancerUS, @WorldBladderCan
We’re headed back to Baltimore! The ECOG-ACRIN Spring 2026 Group Meeting will be held May 5–7, 2026 (Tues–Thurs, note the shift from Wed–Fri). Join us in Baltimore for plenary sessions, networking, and collaboration. Stay tuned for registration details. #EAOnc
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
Active Clinical Trials
Participating Institutions
International Sites

Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
